- Conditions
- Colorectal Cancer, Hereditary Non-polyposis Colon Cancer, Precancerous Condition
- Interventions
- study of socioeconomic and demographic variables, evaluation of cancer risk factors, study of high risk factors
- Other · Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 100 Years
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2353–2376
of 3,058
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer
- Interventions
- DJ-927
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico • Houston, Texas
- Conditions
- Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Benign Colon Tumor, Malignant Colorectal Tumor, Benign Colorectal Neoplasm
- Interventions
- Colorectal resection
- Procedure
- Lead sponsor
- Intuitive Surgical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Andreana Holowatyj, PhD, MSCI
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2037
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Solid Tumor, Adult
- Interventions
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
- Combination Product
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Cancer Screening
- Interventions
- MyChart Priming Message
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 51 Years to 75 Years
- Enrollment
- 3,880 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Westwood, Los Angeles, California
- Conditions
- Colon Cancer, Precancerous Condition, Rectal Cancer
- Interventions
- oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 40 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
- Interventions
- Infliximab, Vedolizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
- Interventions
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Radiation Therapy (RT)
- Radiation
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- San Francisco, California • Walnut Creek, California
- Conditions
- Colorectal Neoplasms
- Interventions
- 1018 ISS immunostimulatory oligonucleotide
- Drug
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Interventions
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6, FOLFIRI, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Kestrel Therapeutics, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- ERAS-601, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
- Interventions
- PEPRR, Pep-Pal
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 538 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Colorectal Cancer Screening
- Interventions
- 3 sample g-SENSA, 2 sample InSure, 1 sample OC-Micron
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 50 Years to 74 Years
- Enrollment
- 2,260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pain, Colorectal Adenomas, Colorectal Cancer
- Interventions
- Air Insufflation method., CO2 insufflation, Water Immersion/CO2, Water Exchange/CO2, Water Immersion/AI, Water Exchange/AI
- Other
- Lead sponsor
- Presidio Ospedaliero Santa Barbara
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Colorectal Cancer
- Interventions
- capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 76
- States / cities
- PARK Springs, Arizona • Sedona, Arizona • Tucson, Arizona + 68 more
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
- Interventions
- NC410, pembrolizumab
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer, Prostate Cancer
- Interventions
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Biological
- Lead sponsor
- Envita Medical Center, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
- Interventions
- cognitive assessment, magnetic resonance imaging, management of therapy complications
- Procedure
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- Not listed
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus, Cancer Colorectal
- Interventions
- CBP-1019
- Drug
- Lead sponsor
- Coherent Biopharma (Hefei) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Cerritos, California • Orlando, Florida • Manhasset, New York + 1 more
- Conditions
- Colorectal Carcinoma
- Interventions
- Best Practice, Health Promotion and Education, Survey Administration
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- LMB-9 immunotoxin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland